Abstract
There has been recent growth in the number and magnitude of clinical trials for various forms of retinal gene therapy. Because of regulatory requirements, and to better understand vector safety profiles, there is a need for standardised and effective methods to collect, process, and store biological samples taken from trial patients that can be used to assess the dissemination of the vector within bodily fluids and any systemic cellular and humoral immune responses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (2015) Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products: guidance for industry. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM404087.pdf. Accessed Aug 2015
Scientific Advisory Committee on Genetic Modification, Health and Safety Executive, UK (2007) The SACGM compendium of guidance, part 6: guidance on the use of genetically modified microorganisms in a clinical setting. http://www.hse.gov.uk/biosafety/gmo/acgm/acgmcomp/part6.pdf. Accessed Jan 2007
International Conference on Harmonisation of Technical Requirements for Registation of Pharmaceuticals for Human Use (2009) ICH considerations: general principles to address virus and vector shedding. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M6/Concept_Paper/Considerations_on_Viral_Vector_Shedding.pdf. Accessed June 2009
Bainbridge JW, Smith AJ, Barker SS et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239
Ghazi NG, Abboud EB, Nowilaty SR et al (2016) Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet 135:327–343
Hauswirth WW, Aleman TS, Kaushal S et al (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19:979–990
MacLaren RE, Groppe M, Barnard AR et al (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383:1129–1137
Maguire AM, Simonelli F, Pierce EA et al (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248
Wan X, Pei H, Zhao MJ et al (2016) Efficacy and safety of rAAV2-ND4 treatment for Leber’s hereditary optic neuropathy. Sci Rep 6:21587
World Health Organization (2007) Standard precautions in health care: aide-memoire. http://www.who.int/csr/resources/publications/EPR_AM2_E7.pdf. Accessed Oct 2007
Acknowledgments
This work was supported by the Oxford University Hospitals NHS Foundation Trust NIHR Biomedical Research Centre, the Wellcome Trust, the Medical Research Council (MRC) EME Programme, and Nightstarx Ltd.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Barnard, A.R., Rudenko, A.N., MacLaren, R.E. (2018). Vector Shedding and Immunogenicity Sampling for Retinal Gene Therapy. In: Boon, C., Wijnholds, J. (eds) Retinal Gene Therapy. Methods in Molecular Biology, vol 1715. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7522-8_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7522-8_27
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7521-1
Online ISBN: 978-1-4939-7522-8
eBook Packages: Springer Protocols